<DOC>
	<DOCNO>NCT00571168</DOCNO>
	<brief_summary>1 . Scientific background In patient multiple myeloma high-dose chemotherapy follow autologous stemcell transplantation prefer conventional therapy , since superiority respect complete remission , complete remission duration , event-free survival overall survival proven within well control clinical trial ( Fassas et al. , 2002 ; Goldschmidt et al. , 2003 ) . Nausea vomit well know distress side-effects high dose chemotherapy regimen . The administration selective 5-HT3-receptor antagonist ( 5-HT3 RAs ) combination corticosteroid ( = antiemetic standard therapy ) effective prevention adverse effect 70 80 % patient . However , 25 40 % patient still suffer vomit nausea delay phase chemotherapy . Superior protection could achieve addition Aprepitant ( EMEND® ) antiemetic standard therapy acute delay phase highly emetogenic chemotherapy . The enhanced antiemetic protection maintain multiple chemotherapy-cycles extent superior standard therapy alone ( de Wit et al. , 2003 ) . Furthermore addition Aprepitant ( EMEND® ) standard therapy generally well tolerated impact chemotherapy-induced nausea vomiting ( CINV ) daily life significantly reduce ( Hesketh et al. , 2003 ; Dando &amp; Perry , 2004 ) . 2 . Trial Rationale Aprepitant ( EMEND® ) selective high-affinity receptor antagonist human substance P/neurokinin-1 ( NK1 ) show inhibit emesis induce cytotoxic chemotherapeutic agent augments antiemetic activity 5-HT3 RAs ( e.g . Granisetron , Ondansetron ) corticosteroid ( e.g . Dexamethasone ) . Thus Aprepitant ( EMEND® ) addition antiemetic standard therapy show possess powerful superior protection report several clinical trial significantly improve acute delay CINV . The aim study evaluate , 7 day high-dose chemotherapy Melphalan ( moderate emetogenic drug ) follow autologous peripheral blood stemcell transplantation , antiemetic treatment regimen respect efficacy safety patient multiple myeloma . To best knowledge effect Aprepitant Melphalan induce CINV never investigate .</brief_summary>
	<brief_title>Efficacy Safety Aprepitant Subjects With Multiple Myeloma During After High-dose Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Men woman &gt; /= 18 year Patients multiple myeloma receive highdose chemotherapy ( Melphalan ) autologous peripheral stemcell transplantation Signed informed consent Patients suffer nausea vomit last 12 hour prior plan highdose chemotherapy Patients receive antiemetic 24 hour prior plan highdose chemotherapy Intake steroid History hypersensitivity investigational product drug similar chemical structure excipient present pharmaceutical form investigational product Simultaneous intake pimozide , terfenadine , astemizole Pregnant nursing woman Mental condition render subject incapable understand nature , scope possible consequence trial Expected noncompliance complete subject´s diary FLIEscore</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>chemotherapy induce nausea vomiting</keyword>
	<keyword>autologous peripheral blood stemcell transplantation</keyword>
	<keyword>high dose chemotherapy</keyword>
</DOC>